DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at AACR Annual Meeting

DelMar Pharmaceuticals (OTCQX:DMPI) presented updated data from an ongoing Phase I/II clinical trial in refractory glioblastoma multiforme (GBM) with its lead anti-cancer product candidate, VAL-083 (dianhydrogalactitol) at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans.
As quoted in the press release:

In summary, DelMar presented that:

• A well-tolerated VAL-083 dosing regimen of 40 mg/m²/daily every 3 days in a 21 day cycle has been selected for advancement into a Phase III refractory GBM study;
• The Phase III study design and initiation shall be determined in consultation with the USDFA during a meeting planned for the first half of 2016;
• The majority of GBM patients enrolled in DelMar’s Phase I/II clinical trial have tumors exhibiting features correlated with resistance to currently available therapies, aggressive disease and poor patient outcomes; and
• This clinical trial is ongoing with expected median survival of eight to nine months following bevacizumab failure.  Results to date support the potential of VAL-083 to offer a clinically meaningful survival benefit and a promising new treatment option for GBM patients who have failed or are unlikely to respond to currently available chemotherapeutic regimens.

DelMar Pharmaceuticals Chairman and CEO, Jeffrey Bacha, stated:

We are pleased with the continued progress and promise of VAL-083 as a potential new treatment for GBM We look forward to discussing our plans for advancement into registration-directed Phase III clinical trials with the USFDA in the coming months.

Connect with DelMar Pharmaceuticals (OTCQX:DMPI) to receive an Investor Presentation.